A fifty-one-year-old partner at a Lagos commercial law firm has not slept properly for twenty months. She wakes at 3:14 most nights, drenched in a sweat she did not have ten years ago, and lies awake until five. By seven she is in chambers. By eleven her concentration is going, by two her temper is going, and by the time she gets home at nine she has nothing left for her husband or her fifteen-year-old. She has gained eight kilograms in eighteen months without changing what she eats. Her mood is one she does not recognise — flatter on some days, sharper on others, never quite hers. Three weeks ago, in a board meeting she has chaired for nine years, she could not produce the name of a colleague she has worked with for fourteen. She covered the moment by reaching for water. She has told no one.
She has put all of it down to stress. She has not seen a gynaecologist about any of it. The word "menopause" has not been spoken in her household, by her, by her husband, or by her doctor.
This is not hypothetical. The symptom pattern she carries is so consistent across women in her demographic — and so consistently misread by everyone around them, including themselves — that the composite reads more truthfully than any single case file would. Half the Nigerian adult population will pass through this transition. Almost none of them will be offered the conversation that turns it from something endured into something managed.
This piece is for that woman, and for the physician who would have placed her symptoms into the right diagnosis the first time she described them.
What menopause actually is, clinically
Menopause is the retrospective marker of a process that begins, on average, a decade earlier. The ovarian follicular reserve declines from a woman's late thirties onward, more steeply through her forties, and the resulting fall in oestradiol and progesterone — with a compensatory rise in FSH — produces the symptom load that defines the perimenopausal years. The diagnosis of menopause itself is the twelve-month anniversary of the final period. By that anniversary, in most women, the symptomatic transition has been underway for between four and ten years.
Most of the clinical action happens in the perimenopausal window. Cycles become irregular, then anovulatory, then absent. Vasomotor symptoms appear, peak, and in most women persist for seven to ten years rather than the two or three older textbooks suggested. The post-menopausal years carry a different problem set: a steep transition in cardiovascular risk, the steepest decade of bone loss in the female lifespan, and the genitourinary changes that quietly compromise sexual function, continence, and infection risk.
None of this is exotic medicine. It is well characterised, holds guideline coverage from the British Menopause Society, NAMS, and the Society for Endocrinology, and sits in the routine practice of every menopause-aware gynaecologist in London, Boston, or Cape Town. The clinical knowledge exists. What does not exist, in Nigerian primary care and most Nigerian gynaecology, is the patient-side conversation that surfaces the symptoms in time for the knowledge to be applied.
The symptoms most often missed
The vasomotor symptoms — hot flushes, night sweats — are the textbook complaint. They are usually recognised. They are also, even when recognised, under-treated. The hormone replacement therapy that would resolve them in most patients is rarely offered. The patient is told it is a phase, that the flushes will pass, that there are dangerous tablets she should avoid, and that she should drink more water.
The symptoms that get missed are the ones that do not announce themselves as menopausal. Individually they look like other things. Together they form a pattern the trained eye sees in seconds and the untrained eye reads as six unrelated complaints.
Sleep disruption. Fragmentation, early waking, the 3 a.m. lie-awake. This is night-sweat physiology breaking sleep architecture, often without the patient remembering she was hot. The cumulative cost is the one the chronically sleep-deprived Nigerian executive carries — usually without being told why.
Cognitive change. Working memory shifts. Word-finding lapses. The names of people one has known for years arriving a beat late. In women, this is overwhelmingly attributed to age or stress, and it is often the symptom that frightens the patient most — because she has watched a parent decline and is afraid she is watching herself do the same. Perimenopausal cognitive change is, in most women, reversible on appropriate hormone therapy. The dementia she privately fears is not what is happening.
Mood change. Anxiety that was not there a year ago. Depressive symptoms that respond poorly to the SSRI a primary-care doctor reaches for because hormonal causation has not been considered. A substantial fraction of new-onset mood disturbance between forty-five and fifty-five is hormonally driven, and responds better to oestrogen than to an antidepressant alone.
Musculoskeletal pain. Generalised joint pain that "feels like arthritis." Frozen shoulder with no injury history. Plantar fasciitis in both feet at once. The literature now uses the term "musculoskeletal syndrome of menopause." It is routinely sent to orthopaedics, physiotherapy, and rheumatology before anyone asks about the patient's cycle.
Genitourinary syndrome of menopause. Vaginal dryness. Painful intercourse. Urinary urgency. Recurrent UTIs that begin in a woman's late forties and become a quarterly event by her mid-fifties. The treatment, in most patients, is a small dose of vaginal oestrogen — local, low systemic absorption, safe in almost all clinical contexts, including in many women for whom systemic HRT is contraindicated. The patient does not know this. She is treating each UTI separately, no longer enjoying sex with her husband, and will not bring either fact into a consultation that does not invite it.
Cardiovascular risk transition. Pre-menopausal women carry, on average, a lower cardiovascular risk profile than men of the same age. That advantage attenuates through the perimenopausal years and is largely gone by sixty. In most Nigerian women, the transition is unmonitored. The cardiovascular benefit of HRT initiated within the appropriate window — the "timing hypothesis" — is not discussed because HRT itself is not discussed.
Bone density. The post-menopausal decade is the steepest period of bone loss in the female lifespan. A Nigerian woman of fifty-five who is not on HRT, not weight-bearing-exercising, and not screened is, by her mid-sixties, at materially elevated fracture risk. DEXA is available in Nigeria. It is rarely ordered in routine gynaecological care.
Each symptom, alone, looks like something else. Together they form a diagnosis being missed serially across the demographic — by patients, family, and doctors trained in an era when the senior instinct on HRT was caution and on menopause was that it is a phase to be endured.
A second patient
A forty-six-year-old entrepreneur in Wuse runs the logistics company she founded eleven years ago. Her cycles have become unpredictable — sometimes a fortnight apart, sometimes ten weeks. She has had four UTIs in a year, treated by two GPs as self-contained episodes. She has gained six kilograms. The anxiety she did not have at forty-four she has now. Her sleep is poor. She has been told, separately, that the UTIs are because she does not hydrate enough, the weight gain because she eats late, the anxiety might benefit from a low-dose SSRI, and the irregular cycles are because she is approaching forty-seven and these things happen.
She is in perimenopause. None of the four doctors who have seen her in the last year have said the word. Each treated each symptom as a separate event. Named once in a single visit, the pattern reorganises the whole picture — which medications she is on, which she comes off, which screenings begin annually now, and which conversation she gets to have with her husband about a year she has been quietly losing.
What proper menopause management actually looks like
The clinical work, when done properly, is not exotic. It is a sequence.
A real symptom history. Not a yes/no question about hot flushes, but a full pass across the seven domains above, with a validated questionnaire — the Greene Climacteric Scale or the Menopause Rating Scale — completed before the consultation. Ten minutes. A structured account of a symptom load the patient herself often did not realise she was carrying.
A baseline workup. The diagnosis of perimenopause is largely clinical, but FSH and oestradiol are useful in premature menopause, in post-hysterectomy patients, and in atypical presentations. A lipid profile, fasting glucose and HbA1c, blood pressure, weight and waist circumference, and a baseline DEXA where indicated.
The HRT conversation, done honestly. This is the part most Nigerian gynaecology gets wrong, and it deserves naming. The 2002 Women's Health Initiative study, which reported elevated risks of breast cancer and cardiovascular events on combined HRT, terrified a generation of clinicians and patients globally. The interpretation has been substantially revised since. The WHI cohort was predominantly women in their sixties starting HRT a decade or more after their final period — a population for whom the risk-benefit balance is genuinely less favourable. Re-analyses through the late 2010s and the 2020s established the "timing hypothesis": HRT initiated within ten years of menopause, or before sixty, carries a meaningfully more favourable profile. Transdermal preparations carry materially lower VTE risk than oral. The breast cancer signal on combined HRT is real but smaller than the 2002 headlines suggested, and heavily modulated by duration, preparation, and baseline risk. In the appropriate timing window the cardiovascular signal is now read as benefit, not harm. Cognitive and bone-density benefits are well established. That conversation, held in those terms, is the standard of care BMS and NAMS have been publishing for years. It is not the conversation most Nigerian women are getting.
Non-hormonal options where HRT is contraindicated. SSRIs and SNRIs for vasomotor symptoms. Vaginal oestrogen alone for the genitourinary syndrome, including in many women for whom systemic HRT is contraindicated. CBT-I for sleep. Resistance training — and the metabolic case for lifting weights is sharper for the post-menopausal woman than for almost any other demographic, because the bone-density and insulin-sensitivity effects compound with the hormonal transition rather than running against it.
Lifestyle work that is real medicine, not a brochure. Weight-bearing exercise three times a week, at a meaningful load. Adequate calcium and vitamin D, with serum levels measured rather than assumed. Alcohol limitation. Sleep protected. Cardiovascular and bone-density follow-up scheduled annually as the post-menopausal years begin.
A third patient, briefly
A fifty-three-year-old executive in Abuja, three years post final period, came in to discuss something else entirely. The symptom history, taken across all seven domains, turned up everything. The HRT conversation was held in the modern frame. She elected a transdermal preparation with cyclical progesterone. The first three months were a titration. By month six she said, in follow-up, that she had not realised, until oestrogen was returned to her body, how thoroughly its absence had reshaped who she had become. The fatigue she had taken for ageing was lifting. The sleep she had taken for poor was returning. The cognitive flatness she had quietly mourned was not, as it turned out, hers. It had been a deficiency state. She had been told, for four years, that it was a phase to be endured.
She is not unusual. She is what proper management produces in an appropriately selected woman. The intervention exists. The patient is not being offered it.
Why the conversation does not happen in Nigeria
Three structural reasons compound.
The first is the cultural script. Menopause is framed in Nigerian household and clinical culture as something women endure quietly, in the same register as the labour pains forty years earlier. The script is not malicious. It is pre-medical. It belongs to a period in which there was nothing meaningful to be done, and a culture of stoicism filled the vacuum. The clinical silence has now been broken in the international literature. The culture has not caught up.
The second is the HRT legacy. The 2002 WHI scare reached Nigerian gynaecology training in the form most readily absorbed by a cautious medical culture — as a contraindication, not a nuance. A generation of Nigerian gynaecologists were trained, formally or informally, that HRT was dangerous and conservative management meant not prescribing it. The post-2017 re-analyses and modern menopause-society position statements have not propagated through Nigerian gynaecological practice in the way they have through their British and American counterparts. A Nigerian woman who reads the international literature for herself often arrives at a consultation better informed about modern HRT than the doctor she has come to see. That is not a comfortable observation. It is, in 2026, true.
The third is the under-supply of menopause-specialist gynaecology. A small number of Lagos and Abuja gynaecologists have built menopause-aware practices and hold the conversation properly. Against the size of the demographic, the number is very small. Most senior Nigerian women of fifty are not sent to one. They are not told one exists. They see a general gynaecologist for an unrelated problem, mention a hot flush, are told it will pass, and leave.
The arc
The first piece in this series was about a diagnosis that arrives, in Nigerian women, an average of nineteen years late. The second was about a surgical decision made too quickly because the conservative options were not in the room. This third is about a transition every woman in the demographic will pass through, and through which almost none of them will be counselled. The fourth, next, is about the women who die in private hospitals their families assumed had protected them.
The thread is the same Nigerian woman, at successive stages, being asked to manage a clinical reality her care system is not assembling for her. The conversation does not happen at twenty when the endometriosis starts, at thirty-eight when the fibroids are diagnosed, at forty-eight when the perimenopause arrives. And the conversation that should have happened in pregnancy was, for those who did not survive it, the one the chart will retrospectively show was not held.
What Kinedic does about it
The annual physical for a female member over forty-five takes, in our practice, a real perimenopausal history. The seven domains are asked about. The validated questionnaire is offered. The HRT conversation is held in the modern frame — current BMS and NAMS guidance, not 2003 caution. Bone-density and cardiovascular screening begin in the perimenopausal years rather than after. The vaginal-oestrogen question, which most patients will not raise themselves, is raised by the physician.
The work is not heroic. It is the standard of care, held seriously, in a setting designed for the conversation to happen.
Closing
The Nigerian woman of fifty has, in 2026, more clinical options than her mother had and substantially more than her grandmother had — and she is being offered, in most cases, fewer of them. The reason is not clinical. The clinical knowledge is settled. The reason is that the conversation that would surface what she needs is not being held — by her doctor, in her household, or in the medical culture around her. It begins with a single consultation in which the seven domains are asked about in plain language, the answers are taken seriously, and the patient leaves with a plan that addresses the diagnosis rather than the embarrassment of having raised it.
The first conversation is private and costs nothing.